Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORM-1153 in Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT07809906Phase 1Recruiting
- Sponsor
- Orum Therapeutics
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ORM-1153 in acute myeloid leukemia (AML), sponsored by Orum Therapeutics. Primary endpoints: Optimal Biological Dose(s) at 24 months, Incidence of Dose Limiting Toxicities at 24 months and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
ORM-1153
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07809906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809906.